Literature DB >> 8725711

Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis.

R R Forastiero1, M E Martinuzzo, L C Kordich, L O Carreras.   

Abstract

Anticardiolipin antibodies (aCL) detected by standard ELISA are found in association with autoimmune and infectious diseases. It is now recognized that beta 2 glycoprotein I (beta 2GPI) is a cofactor for aCL binding to cardiolipin (CL). To examine differences in cofactor requirements, aCL positive sera from patients with the antiphospholipid syndrome (APS) and syphilis were studied. Using an ELISA with human purified beta 2GPI adsorbed onto irradiated plates, we detected high binding activity in 29 out of 35 samples from APS patients and low in only 1 out of 37 aCL positive syphilis sera. Moreover, a good correlation (r = 0.79) was also observed in the former group between aCL and anti beta 2GPI. Whole IgG and affinity purified IgG aCL from APS patients did not bind to CL in the absence of beta 2GPI, but recognized beta 2GPI on irradiated plates in the absence of phospholipids. In contrast, IgG purified from syphilis patients only bound to CL alone. Taken together, these data indicate that performing both ELISA (aCL and anti beta 2GPI) it could be possible to distinguish aCL from autoimmune or infectious diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725711

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

Review 1.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

2.  Binding properties of antibodies to prothrombin and beta2-glycoprotein I (beta2-GPI) assayed by ELISA and dot blot.

Authors:  R R Forastiero; M E Martinuzzo; L O Carreras
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

3.  Antiphospholipid syndrome.

Authors:  M Greaves
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

4.  High prevalence of co-factor independent anticardiolipin antibodies in malaria exposed individuals.

Authors:  P H Consigny; B Cauquelin; P Agnamey; E Comby; P Brasseur; J J Ballet; C Roussilhon
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

Review 5.  The antiphospholipid syndrome and infection.

Authors:  G N Dalekos; K Zachou; C Liaskos
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

6.  Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset.

Authors:  N Nakamura; T Ban; K Yamaji; Y Yoneda; Y Wada
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

7.  Specificity of anti-phospholipid antibodies in infectious mononucleosis: a role for anti-cofactor protein antibodies.

Authors:  M Sorice; V Pittoni; T Griggi; A Losardo; O Leri; M S Magno; R Misasi; G Valesini
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

8.  Antiphosphatidylserine antibodies in patients with autoimmune diseases and HIV-infected patients: effects of Tween 20 and relationship with antibodies to beta2-glycoprotein I.

Authors:  C González; A Lestón; B García-Berrocal; A Sánchez-Rodriguez; J A Martín-Oterino; I Alberca; M Cordero; R Jorge; J A Navajo; J M González-Buitrago
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

9.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

10.  Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease.

Authors:  S Loizou; S Singh; E Wypkema; R A Asherson
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.